Mixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma

被引:128
|
作者
Sapisochin, Gonzalo [1 ,2 ]
Fidelman, Nicholas
Roberts, John P. [1 ]
Yao, Francis Y. [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[2] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Hepatobiliary & Pancreat Surg & Transplantat, E-08193 Barcelona, Spain
关键词
LIVER-TRANSPLANTATION; UNITED-STATES; CIRRHOSIS; RESECTION;
D O I
10.1002/lt.22307
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic cholangiocarcinoma (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, and posttransplant outcomes for patients who underwent transplantation for hepatocellular carcinoma (HCC) and were found to have HCC-CC or I-CC in the explant and (2) to compare the outcomes of these patients with those of controls with HCC who were matched (1:3) by the tumor size and the number of nodules in the explant. In the explant specimens of 10 of 302 patients (3.3%) who underwent liver transplantation (LT) for HCC, mixed HCC-CC or I-CC was identified. There were 4 additional incidental cases of HCC-CC. After a median follow-up period of 32 months, 8 of the 14 patients (57%) suffered from tumor recurrence, and the median disease-free survival time was 8 months. The cumulative risk of tumor recurrence was 40% and 70% at 1 and 5 years, respectively, for these 14 patients. When the 4 incidental cases were excluded, the study group with HCC-CC or I-CC (n = 10) had a significantly lower incidence of well-differentiated tumors (11.1% versus 43.3%, P < 0.02) and a higher rate of recurrence (60% versus 16.7%, P = 0.008) in comparison with the control group of patients with HCC (n = 30). The 1- and 5-year cumulative risks of tumor recurrence were 42% and 65%, respectively, in the study group and 10% and 17%, respectively, in the control group (P < 0.002). The actuarial 1- and 5-year patient survival rates without recurrence were also significantly lower in the study group (79% and 32% in the study group and 90% and 62% in the control group, P < 0.03). Dynamic contrast-enhanced computed tomography or magnetic resonance imaging showed progressive contrast enhancement throughout the arterial and portal venous phases without washout in 8 of the 10 patients. In conclusion, HCC-CC and I-CC are associated with a poor prognosis and a high rate of tumor recurrence after LT, and both tumors exhibit radiographic features that are distinct from those observed with HCC. Liver Transpl 17:934-942, 2011. (C) 2011 AASLD.
引用
收藏
页码:934 / 942
页数:9
相关论文
共 50 条
  • [41] Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States
    Altekruse, Sean F.
    Petrick, Jessica L.
    Rolin, Alicia I.
    Cuccinelli, James E.
    Zou, Zhaohui
    Tatalovich, Zaria
    McGlynn, Katherine A.
    PLOS ONE, 2015, 10 (04):
  • [42] IMPACT OF GENDER AND RACE/ETHNICITY ON HEPATOCELLULAR CARCINOMA, INTRAHEPATIC CHOLANGIOCARCINOMA AND EXTRAHEPATIC CHOLANGIOCARCINOMA
    Bhagat, V.
    Somasundar, P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S650 - S650
  • [43] Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
    Burkhart, Richard A.
    Pawlik, Timothy M.
    CANCER CONTROL, 2017, 24 (03)
  • [44] Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    Terada, T
    Matsunaga, Y
    JOURNAL OF HEPATOLOGY, 2000, 33 (06) : 961 - 966
  • [45] Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
    Yi, Xiao
    Zhu, Jiang
    Liu, Wei
    Peng, Li
    Lu, Cong
    Sun, Ping
    Huang, Lingling
    Nie, Xiu
    Huang, Shi'ang
    Guo, Tiannan
    Zhu, Yi
    MOLECULAR & CELLULAR PROTEOMICS, 2023, 22 (08)
  • [46] Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma
    Yotsawat Pomyen
    Jittiporn Chaisaingmongkol
    Siritida Rabibhadana
    Benjarath Pupacdi
    Donlaporn Sripan
    Chidchanok Chornkrathok
    Anuradha Budhu
    Vajarabhongsa Budhisawasdi
    Nirush Lertprasertsuke
    Anon Chotirosniramit
    Chawalit Pairojkul
    Chirayu U. Auewarakul
    Teerapat Ungtrakul
    Thaniya Sricharunrat
    Kannikar Phornphutkul
    Suleeporn Sangrajang
    Christopher A. Loffredo
    Curtis C. Harris
    Chulabhorn Mahidol
    Xin Wei Wang
    Mathuros Ruchirawat
    Scientific Reports, 13
  • [47] Primary Liver Cancers Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma
    Mejia, Juan C.
    Pasko, Jennifer
    SURGICAL CLINICS OF NORTH AMERICA, 2020, 100 (03) : 535 - 549
  • [48] Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma
    Pomyen, Yotsawat
    Chaisaingmongkol, Jittiporn
    Rabibhadana, Siritida
    Pupacdi, Benjarath
    Sripan, Donlaporn
    Chornkrathok, Chidchanok
    Budhu, Anuradha
    Budhisawasdi, Vajarabhongsa
    Lertprasertsuke, Nirush
    Chotirosniramit, Anon
    Pairojkul, Chawalit U.
    Auewarakul, Chirayu
    Ungtrakul, Teerapat
    Sricharunrat, Thaniya
    Phornphutkul, Kannikar
    Sangrajang, Suleeporn A.
    Loffredo, Christopher C.
    Harris, Curtis
    Mahidol, Chulabhorn
    Wang, Xin Wei
    Ruchirawat, Mathuros
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [49] Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: risk factors similar?
    Xavier, Adhoute
    Paul, Castellani
    Bernard, Pol
    Herve, Perrier
    Manuela, Campanile
    Astrid, Wendt
    Patrick, Beaurain
    Olivier, Monnet
    Guillaume, Penaranda
    Luc, Raoul Jean
    Marc, Bourliere
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 164 - 165
  • [50] The Masquerader: A Case of Intrahepatic Cholangiocarcinoma Mimicking Hepatocellular Carcinoma
    Damughatla, Anirudh R.
    Wadehra, Anshu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1174 - S1175